Blue Cross and Blue Shield of Vermont and The Vermont Health Plan
Overactive Bladder Agents
Enablex®, Gelnique®, Sanctura®, Sanctura XR®, Toviaz®, Vesicare®, Myrbetriq®
Step Therapy Guidelines

DESCRIPTION: OAB agents are competitive antagonist of muscarinic receptors and selectivity for urinary bladder receptors. These agents increase the residual urine volume and decrease detrusor muscle pressure.

INDICATION(S): Treatment of Over Active Bladder

REASONS FOR Step Therapy:
☒ Cost  ☐ Potential for misuse  ☐ Toxicity

CRITERIA for APPROVAL: The patient has had a trial and failure of generic Oxybutynin IR or Oxybutynin XL

REASONS for DENIAL of BENEFIT: Patient does not meet above criteria.

BENEFIT APPROVAL: Approval for two year.